At a glance
ClinicalIndex Comparison RecordN/ACompleted· 203 enrolled
Drug / intervention
no interventionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections
Wyeth is now a wholly owned subsidiary of Pfizer·observational·Posted Jun 29, 2009·Updated Aug 10, 2012
In Brief
An observational study evaluating no intervention for Complicated Intra-Abdominal Infection. Completed, enrolled 203 participants across 13 sites.
Detailed Summary
The objective of this study is to estimate the costs of empiric antibiotic therapy and hospitalization costs for patients with a complicated intra-abdominal infection, and to assess the impact of treatment failure of initial antibiotic empiric therapy on pharmacological and total healthcare costs for these patients in Greece.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsComplicated Intra-Abdominal Infection
CountriesGreece
CollaboratorsPfizer
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2008
First PostedJun 2009
Primary CompletionDec 2010
TodayJul 2026
First PostedJun 29, 2009
Enrollment StartNov 1, 2008
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 17.0 years ago
Interventions
no interventionother
success of the initial empiric treatment